Dr. Rick Greene discusses with Dr. Dana Dominguez the association of adjuvant chemoradiation in resected biliary cancer with improved overall survival compared to chemotherapy alone, as reported in her article, "Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database.”

Article: Adjuvant Chemoradiation in Resected Biliary Adenocarcinoma: Evaluation of SWOG S0809 with a Large National Database | Annals of Surgical Oncology (springer.com)

Dr. Rick Greene discusses with Dr. Alexandra Hernandez the role of social support and neighborhood disadvantage on cortisol, a physiologic marker of stress in patients with breast cancer, as reported at the 2024 SSO Meeting in her abstract, "Lower Social Support Predicts Higher Cortisol for Breast Cancer Patients in Disadvantaged Neighborhoods.”

Dr. Rick Greene discusses with Dr. Timothy Pawlik and Dr. Diamantis Tsilimigras the assessment of perioperative mortality and serious complications among patients undergoing complex cancer surgery by surgical oncology fellowship graduates across different career stages. Dr. Pawlik and Dr. Tsilimigras are co-authors of "Practice Patterns and Outcomes Among Surgical Oncology Fellowship Graduates Performing Complex Cancer Surgery in the United States Across Different Career Stages."

Dr. Rick Greene discusses with Dr. Brett Ecker the association between extent of resection and disease-specific survival  in mucinous and non-mucinous appendiceal adenocarcinomas as reported in his article, "Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies.”

https://doi.org/10.1245/s10434-024-15233-9

Rick Greene, MD, discusses with Lorenzo Ferri, MD, PhD, the long-term survival outcomes of patients with esophageal and junctional adenocarcinoma treated with neoadjuvant docetaxel-based chemotherapy and en bloc transthoracic esophagectomy. Dr. Ferri is author of, "Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network."

Dr. Ferri is Professor of Surgery and Oncology, McGill University; David S. Mulder Chair of Surgery Head, Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Centre; and, Director, Upper G.I. Cancer Program, McGill University, Montreal, Canada.

Rick Greene, MD, discusses with Kathie-Ann Joseph, MD, MPH, the epidemiologic and socioeconomic factors that are associated with breast cancer among black women and an assessment of the implications of these factors for screening in this population. Dr. Joseph is author of, "The Landmark Series—Addressing Disparities in Breast Cancer Screening: New Recommendations for Black Women."

Dr. Joseph is Professor, Department of Surgery at NYU Grossman School of Medicine; Professor, Department of Population Health at NYU Grossman School of Medicine; and, Vice Chair for Diversity and Health Equity for the Department of Surgery and Transplant Institute at NYU Langone Health, New York, NY. 

Rick Greene, MD, discusses with Anthony Villano, MD, a review the American College of Surgeons Commission on Cancer Standard 5.6, which pertains to curative intent colon resections performed for cancer. Dr. Villano is author of "Standardization of Colon Resection for Cancer: An Overview of the American College of Surgeons Commission on Cancer Standard 5.6."

Dr. Villano is the Assistant Professor, Surgical Oncology, in the Department of Surgical Oncology, at Fox Chase Cancer Center in Philadelphia, PA.

Rick Greene, MD, discusses with Jean-Nicolas Vauthey, MD, a comparison of different surgical approaches to synchronous liver metastases from rectal cancer and their analysis of both clinicopathological and biological tumor factors associated with completion of the reverse approach. Professor Vauthey is the senior author of, “Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer.”

Dr. Vauthey is Professor of Surgery and Chief of the Hepato-Pancreato-Biliary Section, and the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX.

Rick Greene, MD, discusses with Patricio M. Polanco, MD, an analysis of three hospital designations, as well as volume status, and their effect on the delivery of care and survival outcomes using a cancer registry database of the second largest state in the USA. Dr. Polanco is co-corresponding author of, “Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?.”

Rick Greene, MD, discusses with Eduardo A. Vega, MD, definitions reported on of benchmark values for gallbladder cancer surgery across an international population as well as geographic differences in gallbladder cancer surgery across multiple continents. Dr. Vega is the senior author of, “Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study.”

Dr. Vega is Assistant Professor of Surgery at Boston University School of Medicine and Hepato-Bilio-Pancreatic surgeon in the Department of Surgery at St. Elizabeth’s Medical Center, Boston, MA.

Full article: Benchmarks and Geographic Differences in Gallbladder Cancer Surgery: An International Multicenter Study | Annals of Surgical Oncology (springer.com)

Rick Greene, MD, discusses with Susan Tsai, MD, MHS, the results of an analysis examining the efficacy of second-line gemcitabine/nab-paclitaxel (GnP) after first-line FOLFIRINOX in the neoadjuvant setting among patients with operable pancreatic cancer who were treated with a total neoadjuvant approach. Dr. Tsai is the senior author of, “CA19-9 Response to First-line Neoadjuvant FOLFIRINOX and Second-line Gemcitabine/nab- Paclitaxel in Patients with Operable Pancreatic Cancer.”

Dr. Tsai is Professor of Surgery and Chief of the Division of Surgical Oncology at The Ohio State University Comprehensive Cancer Center, Columbus, OH.